Wouldn't trust her to run my local boots pharmacy |
Emma W. cant be transferred as nobody wants her!!
Looks like you are stuck with the CEO.
Future bleak for 2025 she will remain to take the hit!! |
Never catch a Falling Knife and this one is sharp with more Issues as Costs since budget increase.
Massive Issues Ahead in 2025... |
The China issue hitting AZN again today. I wonder how 'clean' other pharmas are?
(My post on AZN). |
If Man Utd can get rid of Ten Hag why can’t GSK get rid of Emma Walmsley |
Everyone is marking them Down Down Down!
Smart Investors target price 1000p
How Soon How Low its a disaster!! |
Stifel cuts target to price to 1640p from 1770p |
JP Morgan cuts target price to 1440p from 1550p. |
"There is Trouble Ahead"
With support level broken down the slippery slope continues with another leg down! down! down!
Take a pill it may help!
How Low How Soon !! |
Pressure must be building on Emma. Overpromoted in the name of diversity |
This will put on a pound with some proper leadership |
just bought a few more to hold in my isa. Holding firm Buy and hold |
Not entirely sure it's the bottom Watford but just cant deny the value here now. Hope you bag some tomorrow! |
Yes, also thought that 11 positive P3 readouts was very good; hopefully the majority of these will translate to successful approvals and launches. |
 Positive update from HL
"GSK: full-year guidance confirmed despite weak Q3 vaccine sales
GSK beat Q3 earnings estimates due to growth in its specialty medicines.
Written by Derren Nathan Head of Equity Research Oct 30, 2024
No recommendation
Underlying operating profit rose by 5% to £2.8bn, driven by revenue growth and effective cost management. Underlying earnings per share also grew 5% to 49.7p, ahead of market forecasts of 43.5p.
Free cash flow fell 20% to £1.3bn largely driven by the acquisition of rights to certain vaccine technologies. Net debt has fallen from £15.0bn to £12.8bn since the start of the year.
GSK recognised a £1.8bn charge in relation to the Zantac settlement, with the ‘vast majority’ of cases now settled.
With all full-year guidance unchanged, pointing to underlying operating profit growth in the 11-13% range.
The third-quarter dividend rose from 14p to 15p.
The shares were down 3.6% in early trading.
Our view
GSK’s on track to meet upgraded estimates despite ongoing weakness in it’s vaccine portfolio. Two key products, Arexvy and Shingrix were coming up against headwinds in the important US market. But both products still have the potential to reach new patient populations.
The financial progress is underpinned by excellence in research & development that’s seen 11 positive late stage clinical updates so far this year, and is expected to yield five major product approvals next year. However, there can be no guarantee of continued success. Falling sales of COVID-19 medicines have held back growth but now that they are no longer material, comparatives are becoming less demanding.
Beyond vaccines, the group also has a strong presence in HIV treatments which make up about 20% of total revenues. Its newer HIV treatments are a key part of GSK's future, as generic competitors eat away at pricing power for some of the group's legacy treatments. But the group focus for HIV is shifting to long-acting innovation therapies. And it’s these that have helped capture additional market share and drive double-digit growth for the category in the first half. Apretude is another important product to watch in the space. It’s the only approved medicine in its class and real-world studies have shown it to be 99% effective at preventing HIV infections.
Cancer treatment, although relatively small in terms of current sales, is growing rapidly. Recent approvals and launches in new markets mean there are strong growth drivers for the existing portfolio. The development pipeline looks promising.
Net debt has been coming down and currently sits at under 1.3x forecast cash profits, which we don't see as a major concern. The strong financial position and improving cash generation helps support a prospective dividend yield of 4.4%, but remember, no future payouts to shareholders can be assured.
GSK's valuation is below the long-term average, and significantly less demanding than many of its peers. One reason it’s been held back was uncertainty over the financial impact of alleged cancer links to its heartburn drug Zantac. News that the majority of lawsuits relating to were being settled for $2.2bn materially de-risks the investment case.
Looking ahead, strong execution of the growth strategy and clinical pipeline is likely to be the key focus for shareholders moving forward. So far so good, but remember, the drug approval process is long and expensive, with many treatments never seeing the light of day."
HL forecast the forward PE of 8.6 with a forecast dividend yield of 4.4% |
Good shout. Meant to myself but will add tomorrow but in the 13's was a good buy earlier today - I think! |
Bagged a few this morning in the 13s. Happy with that. |
Added today. Chairman's wife bought as well. |
i think the bottom was this morning |
Average is great when you look at the PE ratio here |
3*
GSK issued a fairly average looking Q3 update this morning, the business remains on track to deliver 2024 outlooks. Total Q3 2024 sales were £8.0 billion which was down -2% AER. Total operating profit was down 86% with total EPS down 100% driven by a £1.8b charge relation to the Zantac settlement, while core operating profit and core EPS were both up 5%. So more modest underlying EPS growth and a line under Zantac litigation. FY24 guidance was confirmed, for 2024 turnover growth of 7% to 9%, core operating profit growth of 11% to 13% and core EPS growth of 10% to 12%...
...from WealthOracle
wealthoracle.co.uk/detailed-result-full/GLEN/927 |
Is there a vaccine for Emma? |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
